These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 25115342)
1. Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study. Arpino G; De Placido S; De Angelis C Anticancer Drugs; 2015 Jan; 26(1):117-22. PubMed ID: 25115342 [TBL] [Abstract][Full Text] [Related]
2. Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib. Symonds L; Linden H; Gadi V; Korde L; Rodler E; Gralow J; Redman M; Baker K; Wu QV; Jenkins I; Kurland B; Garrison M; Smith J; Anderson J; Van Haelst C; ; Specht J Clin Breast Cancer; 2019 Apr; 19(2):e283-e296. PubMed ID: 30737173 [TBL] [Abstract][Full Text] [Related]
3. Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study. Ferrero JM; Hardy-Bessard AC; Capitain O; Lortholary A; Salles B; Follana P; Herve R; Deblock M; Dauba J; Atlassi M; Largillier R Cancer; 2016 Oct; 122(20):3119-3126. PubMed ID: 27412268 [TBL] [Abstract][Full Text] [Related]
4. Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients. Fabi A; Giannarelli D; Malaguti P; Ferretti G; Vari S; Papaldo P; Nisticò C; Caterino M; De Vita R; Mottolese M; Iacorossi L; Cognetti F Drug Des Devel Ther; 2015; 9():6177-83. PubMed ID: 26640370 [TBL] [Abstract][Full Text] [Related]
5. Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. Hamilton E; Kimmick G; Hopkins J; Marcom PK; Rocha G; Welch R; Broadwater G; Blackwell K Clin Breast Cancer; 2013 Dec; 13(6):416-20. PubMed ID: 24099649 [TBL] [Abstract][Full Text] [Related]
6. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA; Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121 [TBL] [Abstract][Full Text] [Related]
7. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life. Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813 [TBL] [Abstract][Full Text] [Related]
8. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Schmid P; Adams S; Rugo HS; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Hegg R; Im SA; Shaw Wright G; Henschel V; Molinero L; Chui SY; Funke R; Husain A; Winer EP; Loi S; Emens LA; N Engl J Med; 2018 Nov; 379(22):2108-2121. PubMed ID: 30345906 [TBL] [Abstract][Full Text] [Related]
9. Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer. Seidman AD; Conlin AK; Bach A; Moynahan ME; Lake D; Forero A; Wright GS; Hackney MH; Clawson A; Norton L; Hudis CA Clin Breast Cancer; 2013 Aug; 13(4):239-246.e1. PubMed ID: 23829890 [TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety. Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989 [TBL] [Abstract][Full Text] [Related]
12. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363 [TBL] [Abstract][Full Text] [Related]
13. Paclitaxel-resistant advanced recurrent breast cancer: a case of partial response due to addition of bevacizumab to paclitaxel therapy: a case report. Ishizuna K; Ninomiya J; Kojima M; Kawashima M; Nozaki M; Yamagishi H; Ueda Y; Oya M BMC Res Notes; 2013 Jul; 6():254. PubMed ID: 23830415 [TBL] [Abstract][Full Text] [Related]
14. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Nahleh ZA; Barlow WE; Hayes DF; Schott AF; Gralow JR; Sikov WM; Perez EA; Chennuru S; Mirshahidi HR; Corso SW; Lew DL; Pusztai L; Livingston RB; Hortobagyi GN Breast Cancer Res Treat; 2016 Aug; 158(3):485-95. PubMed ID: 27393622 [TBL] [Abstract][Full Text] [Related]
15. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. Dranitsaris G; Coleman R; Gradishar W Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958 [TBL] [Abstract][Full Text] [Related]
16. The treatment patterns, efficacy, and safety of nab (®)-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis. Liang C; Li L; Fraser CD; Ko A; Corzo D; Enger C; Patt D BMC Cancer; 2015 Dec; 15():1019. PubMed ID: 26714468 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830 [TBL] [Abstract][Full Text] [Related]
18. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer. Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263 [TBL] [Abstract][Full Text] [Related]
19. Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer. Tanaka S; Iwamoto M; Kimura K; Matsunami N; Morishima H; Yoshidome K; Nomura T; Morimoto T; Yamamoto D; Tsubota Y; Kobayashi T; Uchiyama K Clin Breast Cancer; 2015 Jun; 15(3):191-6. PubMed ID: 25579459 [TBL] [Abstract][Full Text] [Related]
20. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). Rugo HS; Barry WT; Moreno-Aspitia A; Lyss AP; Cirrincione C; Leung E; Mayer EL; Naughton M; Toppmeyer D; Carey LA; Perez EA; Hudis C; Winer EP J Clin Oncol; 2015 Jul; 33(21):2361-9. PubMed ID: 26056183 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]